Source-grounded facts extracted from Intellia Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Intellia Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $15.0 million. Guidance reaffirmed.
“commercial launch for HAE in the first half of 2027. This guidance excludes all potential commercial revenues from lonvo-z. • Collaboration Revenue : Collaboration revenue was $15.0 million for the first quarter of 2026, compared to $16.6 million for the first quarter of 2025. • R&D Expenses : Research and development (R&D) expenses were $80.7 million for the first”
Intellia Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. valued at approximately $194.6 million (effective 2026-04-28).
“On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.”
Intellia Therapeutics, Inc.: Board adopted Fourth Amended and Restated By-laws adding a cure period for deficiencies in shareholder notices and designating federal district courts as exclusive forum for federal securities law actions (effective 2026-04-07).
“On April 7, 2026, based on the recommendation of the nominating and corporate governance committee of the board of directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board adopted amendments to the Company’s Third Amended and Restated By-laws. Under the Fourth Amended and Restated By-laws, which are effective April 7, 2026 (the “Amended By-laws”), the Company added a provision allowing shareholders to cure any facially apparent deficiencies in a shareholder’s timely notice of a nomination or proposal, and requiring the Company to notify the shareholder of any facially apparent deficiencies in a timely notice. In addition, the Amended By-laws designate the federal district courts of the United States as the exclusive forum for resolving any complaint that asserts a cause of action arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Com”
Intellia Therapeutics, Inc. amended Sales Agreement with Jefferies LLC valued at $1,035,316,650 (effective 2026-03-02).
“On March 2, 2026, the Company entered into an amendment to the Sales Agreement to increase the size of the at-the-market offering program from $750,000,000 to $1,035,316,650.”
Birgit Schultes was appointed as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc..
“Birgit Schultes, Ph.D. will become the Company’s Executive Vice President and CSO, effective as of January 13, 2025.”
Laura Sepp-Lorenzino changed role as Special Advisor to the Chief Executive Officer at Intellia Therapeutics, Inc..
“effective January 13, 2025, Dr. Sepp-Lorenzino will become Special Advisor to the Chief Executive Officer of the Company.”
Laura Sepp-Lorenzino departed as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc..
“Laura Sepp-Lorenzino, Ph.D., the Company’s Executive Vice President and Chief Scientific Officer (“CSO”), will retire from the Company and that her anticipated retirement date is December 31, 2025.”
Michael P. Dube was appointed as interim principal financial officer at Intellia Therapeutics, Inc..
“Michael P. Dube, the Company’s Chief Accounting Officer, will serve as the Company’s interim principal financial officer until the Start Date.”
Edward Dulac was appointed as Executive Vice President and Chief Financial Officer at Intellia Therapeutics, Inc..
“the Company announced the appointment, effective July 22, 2024 (“Start Date”), of Edward Dulac to serve as Executive Vice President and Chief Financial Officer (“CFO”), treasurer and principal financial officer of the Company.”
Glenn Goddard departed as Chief Financial Officer at Intellia Therapeutics, Inc..
“the Company also announced that Glenn Goddard, the Company’s current CFO, will step down effective June 30, 2024.”
Brian Goff was appointed as Class I Director at Intellia Therapeutics, Inc..
“On June 12, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Brian Goff, as a Class I director, effective as of June 13, 2024, with a term expiring at the 2026 annual meeting of stockholders.”
Intellia Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended March 31, 2024.”
Michael P. Dube was appointed as principal accounting officer at Intellia Therapeutics, Inc..
“On April 10, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) appointed Michael P. Dube, 46, as principal accounting officer of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.